Oral Losartan in Prevention of Post-ERCP Paancreatitis
Phase 1
Completed
- Conditions
- Post-ERCP Acute Pancreatitis
- Interventions
- Drug: oral losatan
- Registration Number
- NCT04049734
- Lead Sponsor
- Ain Shams University
- Brief Summary
Oral losartan given in the dose of 50 mg one hour before ERCP was studied in the prevention of post ERCP pancreatitis in 50 patients indicated for ERCP in comparison with another 50 patients underwent ERCP without receiving oral losartan.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Any adult patient indicated for ERCP
- Patients with obstructive jaundice.
- Patients with dilated intra-hepatic or extra-hepatic bile ducts due to malignant or benign lesions.
Read More
Exclusion Criteria
- Patients refusing to undergo the procedure or signing the informed consent
- Patients with clinically evident acute pancreatitis before the procedure
- Patients with previous endoscopic or surgical sphincterotomy
- Patients with current use of losartan
- Patients who are allergic or hypersensitive to losartan or hydro soluble contrast solutions
- Patients receiving NSAIDS within a week prior to assessment
- Patients with severe co-morbid conditions as cardiovascular disease, renal failure or decompensated liver cirrhosis.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description patients received the oral losartan oral losatan 50 patients with obstructive jaundice indicated for ERCP and received oral losartan 1 hour before ERCP as a prophylaxis of post-ERCP pancreatitis
- Primary Outcome Measures
Name Time Method Number of participants with development of acute pancreatitis 24 hours Number of participants with development of abdominal pain and elevated serum amylase and/or lipase
- Secondary Outcome Measures
Name Time Method